Daniel J. O’connor Acquires 16,667 Shares of OncoSec Medical Inc (ONCS) Stock
OncoSec Medical Inc (NASDAQ:ONCS) CEO Daniel J. O’connor purchased 16,667 shares of OncoSec Medical stock in a transaction on Monday, February 5th. The shares were acquired at an average cost of $1.50 per share, for a total transaction of $25,000.50. Following the purchase, the chief executive officer now owns 16,667 shares in the company, valued at $25,000.50. The acquisition was disclosed in a document filed with the SEC, which is available through this link.
OncoSec Medical Inc (ONCS) opened at $1.74 on Thursday. The firm has a market capitalization of $76.44, a price-to-earnings ratio of -1.64 and a beta of 3.34. OncoSec Medical Inc has a 52-week low of $0.88 and a 52-week high of $2.95.
ONCS has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of OncoSec Medical in a research note on Thursday, November 9th. Maxim Group set a $5.00 price target on OncoSec Medical and gave the stock a “buy” rating in a research note on Thursday, December 14th. Finally, ValuEngine lowered OncoSec Medical from a “sell” rating to a “strong sell” rating in a research report on Friday, December 1st. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $5.33.
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.